Insider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Director Sells $1,340,510.00 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Director A. Sinclair Dunlop sold 37,000 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $36.23, for a total value of $1,340,510.00. Following the transaction, the director now owns 100,000 shares of the company’s stock, valued at $3,623,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

A. Sinclair Dunlop also recently made the following trade(s):

• On Friday, June 21st, A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $39.24, for a total value of $1,451,880.00.

Apellis Pharmaceuticals Stock Up 3.1 %

Shares of Apellis Pharmaceuticals stock opened at $36.73 on Friday. Apellis Pharmaceuticals, Inc. has a 12-month low of $33.49 and a 12-month high of $73.80. The firm has a market capitalization of $4.46 billion, a PE ratio of -10.62 and a beta of 0.88. The company has a quick ratio of 4.18, a current ratio of 5.08 and a debt-to-equity ratio of 1.73. The stock’s fifty day moving average is $38.01 and its 200-day moving average is $44.00.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.03. The company had revenue of $199.70 million during the quarter, compared to analyst estimates of $190.89 million. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The business’s quarterly revenue was up 110.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.02) earnings per share. Equities analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.29 earnings per share for the current year.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Apellis Pharmaceuticals by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 9,555,678 shares of the company’s stock worth $572,003,000 after buying an additional 85,701 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Apellis Pharmaceuticals by 38.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,460,339 shares of the company’s stock valued at $147,277,000 after acquiring an additional 677,098 shares in the last quarter. Fiera Capital Corp increased its holdings in shares of Apellis Pharmaceuticals by 47.7% in the 2nd quarter. Fiera Capital Corp now owns 1,401,190 shares of the company’s stock valued at $53,750,000 after purchasing an additional 452,753 shares during the period. Norges Bank purchased a new stake in shares of Apellis Pharmaceuticals in the fourth quarter worth approximately $56,640,000. Finally, Frazier Life Sciences Management L.P. boosted its holdings in shares of Apellis Pharmaceuticals by 44.2% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 885,165 shares of the company’s stock worth $52,986,000 after purchasing an additional 271,122 shares during the period. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on APLS shares. Wedbush raised their price target on Apellis Pharmaceuticals from $38.00 to $41.00 and gave the company a “neutral” rating in a report on Friday, August 9th. Needham & Company LLC reissued a “buy” rating and set a $85.00 target price on shares of Apellis Pharmaceuticals in a research note on Friday, August 9th. Piper Sandler started coverage on shares of Apellis Pharmaceuticals in a research report on Friday, May 31st. They set a “neutral” rating and a $46.00 price target on the stock. HC Wainwright decreased their price objective on shares of Apellis Pharmaceuticals from $92.00 to $83.00 and set a “buy” rating for the company in a report on Friday, August 2nd. Finally, JPMorgan Chase & Co. dropped their target price on Apellis Pharmaceuticals from $64.00 to $57.00 and set an “overweight” rating on the stock in a report on Friday, September 13th. Four research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $71.67.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).